With Cutting-edge Technologies
We develop leading edge therapies for various cancers by combining next-generation In-silico Neoantigen Identification Methods with Built-in lentiviral vector-based platform.READ MORE
As participant in projects led by the Ministry of Science & Technology and China National Health Commission, we actively contribute to the prevention and control of infectious diseases.READ MORE
As a CDMO, we offer effective solutions from clinical trials to commercialization, as well as delivery of safe and reliable viral vectors to accommodate our customers' needs.READ MORE
Exclusive license of multiple patents and other intellectual property owned by the Pasteur Institute and Theravectys.
Jinwei's lentiviral vector products were used in first-in human phase I/II HIV clinical trial.
Worldwide license and multiple proprietary know-how to manufacture lentiviral vector-based products and other applications.
Partnership with the Huashan Hospital. Participant in projects led by the Ministry of Science & Technology and China National Health Commission.
State-of-the-art laboratory and GMP compliant production facility in accordance to main regulation authorities (FDA, EMA, CFDA and etc).
Shanghai Jinwei Biotechnology Co., Ltd. (Jinwei) is a biotechnology company dedicated to pursue innovative technology to develop cures for people with serious and life-threatening diseases.
A lentiviral vector carries antigen genes from a pathogen or tumor cell.
The lentiviral vector transcripts and releases the mRNA that encodes the antigen into the dendritic cell.
Dendritic cells presents the antigens to T cells.
T cells recognize the antigens and kill the antigen-bearing cells (pathogens, infected or tumor cells).